Sleep Disorders Trial, Recruiting NCT06773143 Sponsor: Nanjing First Hospital, Nanjing Medical University Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT06773143
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with breast cancer, confirmed through lab and tissue testing
  • People who are currently receiving chemotherapy before surgery (known as neoadjuvant chemotherapy)
  • People aged between 18 and 65 years old
  • People rated as ASA Grade I to III, which is a medical assessment of overall physical health before a procedure (confirm with trial site)
  • People with a body mass index (BMI) between 18 and 30 kg/m²

Who may not be able to join:

  • People who do not wish to take part in the study
  • People with a BMI higher than 30 kg/m²
  • People with a recent history of drug abuse
  • People who are allergic to esketamine or for whom esketamine is medically unsuitable
  • People who have difficulty with memory, thinking, or communication
  • People with serious problems affecting major organs such as the liver or kidneys

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: xiaoliang wang, The First Affiliated Hospital with Nanjing Medical University

Phone: +8615366110306

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Nanjing First Hospital, Nanjing Medical University
Registry
ClinicalTrials.gov
Start date
30 December 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence of PSD on postoperative day -1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov